Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database

Hepatoid adenocarcinoma of the lung (HAL) is a rare malignant tumor that is defined as a primary alpha-fetoprotein (AFP)-producing lung carcinoma. We aimed to identify prognostic factors associated with the survival of patients with HAL using data from the Surveillance, Epidemiology, and End Results...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lei Lei, Yang Liu, Xu Yang-yang, Chen Hua-fei, Zhan Ping, Wang Wen-xian, Xu Chun-wei
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	nsclc hal seer survival Medicine R
Acceso en línea:	https://doaj.org/article/76911e27de92481ca923446d1e9db52a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:76911e27de92481ca923446d1e9db52a
record_format	dspace
spelling	oai:doaj.org-article:76911e27de92481ca923446d1e9db52a2021-12-05T14:10:53ZHepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database2391-546310.1515/med-2021-0215https://doaj.org/article/76911e27de92481ca923446d1e9db52a2021-01-01T00:00:00Zhttps://doi.org/10.1515/med-2021-0215https://doaj.org/toc/2391-5463Hepatoid adenocarcinoma of the lung (HAL) is a rare malignant tumor that is defined as a primary alpha-fetoprotein (AFP)-producing lung carcinoma. We aimed to identify prognostic factors associated with the survival of patients with HAL using data from the Surveillance, Epidemiology, and End Results (SEER) database. We collected data from patients diagnosed with HAL, adenocarcinoma (ADC), and squamous cell carcinoma (SCC) of the lung between 1975 and 2016 from the SEER database. The clinical features of patients with ADC and SCC of the lung were also analyzed. The clinical features of HALs were compared to ADCs and SCCs. A chi-square test was used to calculate the correlations between categorical variables, and a t test or Mann–Whitney U test was used for continuous variables. The Kaplan–Meier method and Cox regression analysis were used to identify the prognostic factors for the overall survival (OS) of HALs. Two-tailed p values < 0.05 were considered statistically significant. Sixty-five patients with HAL, 2,84,379 patients with ADC, and 1,86,494 with SCC were identified from the SEER database. Fewer males, advanced stages, and more chemotherapy-treated HALs were found. Compared to patients with SCC, patients with HAL were less likely to be male, more likely to be in an advanced stage, and more likely to receive chemotherapy (p < 0.05). The American Joint Committee on Cancer staging was the only prognostic factor for OS in patients with HAL, and stage IV was significantly different from other stages (hazard ratio = 0.045, 95% confidence interval: 0.005–0.398, p = 0.005). Males with HAL were more likely to receive radiotherapy compared to females with HAL (61.8 vs 31.5%, p = 0.034). Younger patients with HAL were more likely to receive chemotherapy (59.4 + 10.2 years vs 69 + 11.3 years, p = 0.001). The primary tumor size of HAL was associated with the location of the primary lesion (p = 0.012). No conventional antitumor therapies, including surgery, chemotherapy, and radiotherapy, were shown to have a significant survival benefit in patients with HAL (p > 0.05). This study showed that stage IV was the only prognostic factor for OS in HALs compared to other clinicopathologic factors. Conventional antitumor therapies failed to show survival benefit; thus, a more effective method by which to treat HAL is needed. Interestingly, the clinical features and the location of the primary lesion were shown to be associated with primary tumor size and treatment in patients with HAL, which have not been reported before.Lei LeiYang LiuXu Yang-yangChen Hua-feiZhan PingWang Wen-xianXu Chun-weiDe GruyterarticlensclchalseersurvivalMedicineRENOpen Medicine, Vol 16, Iss 1, Pp 169-174 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nsclc hal seer survival Medicine R
spellingShingle	nsclc hal seer survival Medicine R Lei Lei Yang Liu Xu Yang-yang Chen Hua-fei Zhan Ping Wang Wen-xian Xu Chun-wei Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
description	Hepatoid adenocarcinoma of the lung (HAL) is a rare malignant tumor that is defined as a primary alpha-fetoprotein (AFP)-producing lung carcinoma. We aimed to identify prognostic factors associated with the survival of patients with HAL using data from the Surveillance, Epidemiology, and End Results (SEER) database. We collected data from patients diagnosed with HAL, adenocarcinoma (ADC), and squamous cell carcinoma (SCC) of the lung between 1975 and 2016 from the SEER database. The clinical features of patients with ADC and SCC of the lung were also analyzed. The clinical features of HALs were compared to ADCs and SCCs. A chi-square test was used to calculate the correlations between categorical variables, and a t test or Mann–Whitney U test was used for continuous variables. The Kaplan–Meier method and Cox regression analysis were used to identify the prognostic factors for the overall survival (OS) of HALs. Two-tailed p values < 0.05 were considered statistically significant. Sixty-five patients with HAL, 2,84,379 patients with ADC, and 1,86,494 with SCC were identified from the SEER database. Fewer males, advanced stages, and more chemotherapy-treated HALs were found. Compared to patients with SCC, patients with HAL were less likely to be male, more likely to be in an advanced stage, and more likely to receive chemotherapy (p < 0.05). The American Joint Committee on Cancer staging was the only prognostic factor for OS in patients with HAL, and stage IV was significantly different from other stages (hazard ratio = 0.045, 95% confidence interval: 0.005–0.398, p = 0.005). Males with HAL were more likely to receive radiotherapy compared to females with HAL (61.8 vs 31.5%, p = 0.034). Younger patients with HAL were more likely to receive chemotherapy (59.4 + 10.2 years vs 69 + 11.3 years, p = 0.001). The primary tumor size of HAL was associated with the location of the primary lesion (p = 0.012). No conventional antitumor therapies, including surgery, chemotherapy, and radiotherapy, were shown to have a significant survival benefit in patients with HAL (p > 0.05). This study showed that stage IV was the only prognostic factor for OS in HALs compared to other clinicopathologic factors. Conventional antitumor therapies failed to show survival benefit; thus, a more effective method by which to treat HAL is needed. Interestingly, the clinical features and the location of the primary lesion were shown to be associated with primary tumor size and treatment in patients with HAL, which have not been reported before.
format	article
author	Lei Lei Yang Liu Xu Yang-yang Chen Hua-fei Zhan Ping Wang Wen-xian Xu Chun-wei
author_facet	Lei Lei Yang Liu Xu Yang-yang Chen Hua-fei Zhan Ping Wang Wen-xian Xu Chun-wei
author_sort	Lei Lei
title	Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
title_short	Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
title_full	Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
title_fullStr	Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
title_full_unstemmed	Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
title_sort	hepatoid adenocarcinoma of the lung: an analysis of the surveillance, epidemiology, and end results (seer) database
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/76911e27de92481ca923446d1e9db52a
work_keys_str_mv	AT leilei hepatoidadenocarcinomaofthelungananalysisofthesurveillanceepidemiologyandendresultsseerdatabase AT yangliu hepatoidadenocarcinomaofthelungananalysisofthesurveillanceepidemiologyandendresultsseerdatabase AT xuyangyang hepatoidadenocarcinomaofthelungananalysisofthesurveillanceepidemiologyandendresultsseerdatabase AT chenhuafei hepatoidadenocarcinomaofthelungananalysisofthesurveillanceepidemiologyandendresultsseerdatabase AT zhanping hepatoidadenocarcinomaofthelungananalysisofthesurveillanceepidemiologyandendresultsseerdatabase AT wangwenxian hepatoidadenocarcinomaofthelungananalysisofthesurveillanceepidemiologyandendresultsseerdatabase AT xuchunwei hepatoidadenocarcinomaofthelungananalysisofthesurveillanceepidemiologyandendresultsseerdatabase
_version_	1718371612636479488

Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database

Ejemplares similares